LAB in the 13F filings
Standard Biotools Inc · CUSIP 34385P108
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 11 Feb 2026
- Managers listing it
- 14
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 2 listed it in both
- Shares listed
- 73,049,908
- combined, among listed positions
- Reported value
- $93m
- combined, at the quarter end
Among the 92 comparable managers: 7 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,872,562.
Managers listing LAB in Q4 2025
14 of 14 holders
Largest increases and reductions, by shares
Increases
- Millennium Management LLCexisting position · 3,387,428 shares now+1,933,853
- Citadel Advisors LLCexisting position · 1,076,361 shares now+587,918
- Jane Street Group LLCexisting position · 769,231 shares now+376,212
- Point72 Asset Management LPnew position · 143,307 shares now+143,307
- ARK Investment Management LLCexisting position · 3,066,665 shares now+44,937
Reductions
- Neuberger Berman Group LLCexisting position · 4,624,465 shares now-101,347
- AQR Capital Management LLCexisting position · 419,553 shares now-68,546
- Fidelity (FMR LLC)existing position · 15,592 shares now-2,770
- Invesco Ltdexisting position · 186,768 shares now-1,385
New positions and exits
New (1)
Exited (1)
- Balyasny Asset Management LLCwas $112k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2015 | 1 | $6.5m | n.a. | n.a. |
| Q4 2015 | 1 | $8.6m | n.a. | n.a. |
| Q1 2016 | 2 | $9.9m | n.a. | n.a. |
| Q2 2016 | 3 | $10m | n.a. | n.a. |
| Q3 2016 | 2 | $6.7m | n.a. | n.a. |
| Q4 2016 | 2 | $6.1m | n.a. | n.a. |
| Q1 2017 | 1 | $100k | n.a. | n.a. |
| Q1 2018 | 1 | $873k | n.a. | n.a. |
| Q2 2018 | 2 | $2.0m | n.a. | n.a. |
| Q3 2018 | 4 | $41m | n.a. | n.a. |
| Q4 2018 | 4 | $60m | n.a. | n.a. |
| Q1 2019 | 6 | $101m | n.a. | n.a. |
| Q2 2019 | 5 | $89m | n.a. | n.a. |
| Q3 2019 | 3 | $9.5m | n.a. | n.a. |
| Q4 2019 | 1 | $5.9m | n.a. | n.a. |
| Q1 2020 | 2 | $4.3m | n.a. | n.a. |
| Q2 2020 | 1 | $5.3m | n.a. | n.a. |
| Q3 2020 | 5 | $51m | n.a. | n.a. |
| Q4 2020 | 4 | $13m | n.a. | n.a. |
| Q1 2021 | 1 | $2.2m | n.a. | n.a. |
| Q2 2021 | 1 | $1.2m | n.a. | n.a. |
| Q3 2021 | 1 | $843k | n.a. | n.a. |
| Q4 2021 | 1 | $585k | n.a. | n.a. |
| Q1 2024 | 2 | $194m | 2 | 0 |
| Q2 2024 | 2 | $126m | 0 | 1 |
| Q3 2024 | 2 | $130m | 0 | 1 |
| Q4 2024 | 2 | $108m | 0 | 1 |
| Q1 2025 | 2 | $67m | 1 | 0 |
| Q2 2025 | 2 | $74m | 0 | 1 |
| Q3 2025 | 2 | $80m | 0 | 1 |
| Q4 2025 | 2 | $79m | 7 | 5 |
| Q1 2026 | 1 | $54m | 8 | 4 |
| Q2 2026 | 1 | $48m | 18 | 5 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LAB and LLY →LAB and JNJ →LAB and VRTX →Choose a stock to compare with LAB →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LAB, latest filings →Back to the 13F Explorer →